GenEng News  Dec 23  Comment 
Vifor Pharma and ChemoCentryx have added a second kidney disease therapeutic candidate to their existing renal diseases collaboration. The expanded deal covers ChemoCentryx’s oral CCR2 inhibitor, CCX140, which has successfully completed a Phase...
Benzinga  Dec 22  Comment 
ChemoCentryx Inc (NASDAQ: CCXI) has expanded its kidney health partnership with Vifor Pharma to include the development and commercialization of CCX140 for renal diseases. CCX140 has previously completed a successful Phase II clinical trial in...


ChemoCentryx, Inc. (NASDAQ:CCXI) is a biotechnology company which is developing drugs to help treat Crohn's disease and rheumatoid arthritis. The company's focus has been to target the chemokine system, a system which is known to drive the inflammation process. Using its research platform, Chemocentryx plans to develop future drugs built around targeting the same or similar systems. At the time of its IPO, Chemocentryx did not have any FDA approved drugs.[1]

Business Overview

Chemocentryx was pre-commercially approved drug at the time of its IPO. As a result, its revenues were from collaborative research. In the first nine months of 2011, they reported $5.6M of such revenues and a net loss of $22.8M. The same period in the previous year resulted in $21.7M in revenues and a net loss of $8.2M. [2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on February 8, 2012. The company offered 4.5M shares each for $10. This was below the $14-$16 initial price range. The deal raised a total of $45M. The lead mangers of the deal were JP Morgan, Citi, and Cowen Group (COWN).[3]

Trends & Forces

Reliance on Large Pharmaceutical Companies

Chemocentryx has entered into strategic agreements with GlaxoSmithKline (GSK). These agreements provide for Chemocentryx to conduct the initial clinical trials of candidate drugs and for GSK to pay for and complete the Phase III as well as the marketing and commercialization. Through this agreement, GSK is given the option to exlusively license Chemocentryx's product. While this agreement passes risks and costs associated with drug development to GSK, it also makes Chemocentryx reliant on GSK's abilities to conduct advanced clinical trials and effectively commercialize a product. [4]

  1. CCXI S-1/A 2012 PROSPECTUS SUMMARY "Overview" pg1-3
  3. Renaissance Capital - IPO Home "ChemoCentryx prices downsized IPO at $10, below the range" 8 Feb 2012
  4. CCXI S-1/A 2012 PROSPECTUS SUMMARY "Risk Factors" pg11-13
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki